GILOU 3 mg Tabletten

Negara: Belanda

Bahasa: Belanda

Sumber: CBG-MEB (College ter Beoordeling van Geneesmiddelen)

Bahan aktif:

IVERMECTINE

Tersedia dari:

Substipharm

Kode ATC:

P02CF01

INN (Nama Internasional):

IVERMECTINE

Bentuk farmasi:

Tablet

Komposisi:

BUTYLHYDROXYANISOL (E 320) ; CELLULOSE, MICROKRISTALLIJN (E 460) ; MAGNESIUMSTEARAAT (E 470b) ; ZETMEEL, GEPREGELATINEERD,

Rute administrasi :

Oraal gebruik

Area terapi:

Ivermectin

Ringkasan produk:

Hulpstoffen: BUTYLHYDROXYANISOL (E 320); CELLULOSE, MICROKRISTALLIJN (E 460); MAGNESIUMSTEARAAT (E 470b); ZETMEEL, GEPREGELATINEERD;

Tanggal Otorisasi:

2018-04-25

Selebaran informasi

1
PACKAGE LEAFLET: INFORMATION FOR THE USER
GILOU 3 MG TABLETTEN
Ivermectin
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS IMPORTANT
INFORMATION FOR YOU.

Keep this leaflet. You may need to read it again.

If you have any further questions, ask your doctor or pharmacist.

This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.

If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What GILOU is and what it is used for
2.
What you need to know before you take GILOU
3.
How to take GILOU
4.
Possible side effects
5.
How to store GILOU
6.
Contents of the pack and other information
1.
WHAT GILOU IS AND WHAT IT IS USED FOR
GILOU contains a medicine called ivermectin. This is a type of
medicine which is used for infections
caused by some parasites.
It is used to treat:

an infection in your gut called intestinal strongyloidiasis
(anguillulosis). This is caused by a
type of round worm called _“_Strongyloides stercoralis”.

an infection of your blood called microfilaraemia due to “lymphatic
filariasis”. This is caused
by an immature worm called “Wuchereria bancrofti”. GILOU does not
work against adult
worms, only against immature worms.

skin mites (scabies). This is when tiny mites burrow under your skin.
This can cause severe
itching. GILOU should only be taken when your doctor has proven or
thinks you have scabies.
GILOU WILL NOT STOP YOU FROM GETTING ONE OF THESE INFECTIONS. It does
not work against adult
worms.
GILOU should only be taken when your doctor has proven or thinks you
have a parasite infection.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE GILOU
DO NOT TAKE GILOU
if you are allergic to ivermectin or any of the other ingredients of
this medicine (listed in section 6).
In general, if you experience unusual symptoms that suddenl

Karakteristik produk

1
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE MEDICINAL PRODUCT
GILOU 3 mg Tabletten
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
1 tablet contains 3 mg of ivermectin.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Tablet
The tablets are round, white or almost white, flat chamfered with a
diameter of 5.5 mm and thickness
of 2.1 mm.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS

Treatment of gastrointestinal strongyloidiasis (anguillulosis).

Treatment of suspected or diagnosed microfilaraemia in patients with
lymphatic filariasis due to
_Wuchereria bancrofti_.

Treatment of human sarcoptic scabies. Treatment is justified when the
diagnosis of scabies has
been established clinically and/or by parasitological examination.
Without formal diagnosis
treatment is not justified in case of pruritus.
Official guidelines should be taken into consideration. Official
guidelines will normally include WHO
and public health authorities’ guidelines.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
Treatment of gastrointestinal strongyloidiasis
The recommended dosage is one single oral dose of 200 micrograms of
ivermectin per kg body
weight.
For guidance, the dose, as determined by the patient’s weight, is as
follows:
BODY WEIGHT (KG)
DOSE (NUMBER OF 3 MG TABLETS)
15 to 24
one
25 to 35
two
36 to 50
three
51 to 65
four
66 to 79
five
≥ 80
six
Treatment of microfilaraemia caused by _Wuchereria bancrofti _
2
The recommended dosage for mass distribution for the treatment of
microfilaraemia caused by
_Wuchereria bancrofti _is a single oral dose once every 6 months
designed to provide approximately
150 to 200 μg/kg of body weight._ _
In endemic areas where treatment can only be administered once every
12 months, the recommended
dosage is 300 to 400 μg/kg of body weight to maintain adequate
suppression of microfilaraemia in
treated patients.
For guidance, the dose, as determined by the patient’s weight, is as
follows:
BODY WEIGHT (KG)
DOSE WHEN GIVEN ONCE EVERY 6
MONTHS (NUMBER OF